Viferon, rectal 500000 me 10 pcs

Interferon alpha-2b human recombinant has antiviral, immunomodulatory, antiproliferative properties, suppresses replication of RNA- and DNA-containing viruses. The immunomodulatory properties of interferon alfa-2b, such as increasing the phagocytic activity of macrophages and increasing the specific cytotoxicity of lymphocytes toward the target cells, determine its mediated antibacterial activity.

In the presence of ascorbic acid and alpha-tocopherol acetate the specific antiviral activity of interferon alfa-2b increases and its immunomodulatory activity increases which allows to increase the effectiveness of the body’s own immune response to pathogenic microorganisms.

In application of the preparation the level of secretory immunoglobulins of class A increases, the level of immunoglobulin E normalizes and the endogenous system of interferon alfa-2b is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, possess anti-inflammatory, membrane stabilizing and regenerating properties.

With VIFERON® administration it was found out that no side effects appeared during parenteral administration of interferon-alpha-2b preparations, no antibodies neutralizing anti-viral activity of interferon-alpha-2b were formed. VIFERON® usage in combination therapy enables to decrease therapeutic doses of antibacterial and hormonal drugs, as well as decrease the toxic effects of this therapy.

Cocoa butter contains phospholipids which do not allow the use of synthetic toxic emulsifiers and the presence of polyunsaturated fatty acids facilitates the introduction and dissolution of the product.

Indications

– Acute respiratory viral infections, including influenza, including those complicated by bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of the complex therapy;

– Infectious and inflammatory diseases of newborn children, including premature babies: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus, enterovirus infection, candidiasis, including visceral, mycoplasmosis) in the complex therapy;

– Chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including combination of plasmapheresis and hemosorption in chronic viral hepatitis with severe activity, complicated with liver cirrhosis;

Active ingredient

Composition

1 suppository VIFERON® 500000 IU contains the active ingredient:

interferon alpha-2b human recombinant 500000 IU,

excipients:

ascorbic acid 0.0081 g,

sodium ascorbate 0.0162 g,

alpha-tocopherol acetate 0.055 g,

Dihydrate dihydrate 0.0001 g,

Polysorbate-80 0.0001 g,

Cocoa butter 0.1941 g,

Confectionary fat or cocoa butter substitute up to 1 g.

How to take, the dosage

The drug is used rectally. One suppository contains as an active substance human recombinant interferon alpha-2b in the indicated dosages (150,000 IU, 500,000 IU, 100,000 IU, 300,000 IU).

Acute respiratory viral infections including influenza complicated by bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as a part of complex therapy.

The recommended dose for adults, including pregnant women and children over 7 years old VIFERON® 500000 IU, 1 suppository 2 times per day, 12 hours a day for 5 days. If clinically indicated, therapy may be continued.

In children under 7 years of age, including newborns and premature infants with gestational age of more than 34 weeks, the use of the preparation

VIFERON® 500000 IU 1 suppository 2 times per day every 12 hours daily for 5 days. The therapy can be continued under clinical indications. The break between the courses is 5 days.

In premature infants with gestational age of less than 34 weeks we recommend to use VIFERON® 150,000 IU

1 suppository 3 times daily every 8 hours for 5 days.

The therapy may be continued if clinically indicated. The break between courses is 5 days.

Infectious and inflammatory diseases of newborn children, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) in the complex therapy.

The recommended dose for newborns, including premature infants with gestational age of more than 34 weeks, VIFERON® 150000 IU 1 suppository 12 hours a day. The course of treatment is 5 days.

In premature newborns with gestational age of less than 34 weeks, we recommend to use VIFERON® 150000 IU 1 suppository 3 times daily every 8 hours. The course of treatment is 5 days.

The recommended number of courses for various infectious and inflammatory diseases: sepsis – 2-3 courses, meningitis – 1-2 courses, herpes infection – 2 courses, enterovirus infection – 1-2 courses, cytomegalovirus infection – 2-3 courses, mycoplasmosis, candidiasis, including visceral infection – 2-3 courses. The break between courses is 5 days. Under clinical indications the therapy may be continued.

Chronic viral hepatitis B, C, D in children and adults during complex therapy, including combination of plasmapheresis and hemosorption in chronic viral hepatitis with severe activity and complicated liver cirrhosis.

The recommended dose for adults is VIFERON® 3000000 IU 1 suppository 2 times a day every 12 hours daily for 10 days, and then three times a week every other day for 6-12 months. Treatment duration is determined by clinical efficacy and laboratory indexes.

In children under 6 months of age, 300,000-500,000 IU per day is recommended; 6 to 12 months of age, 500,000 IU per day.

In children aged 1 to 7 years, 300,000,000 IU per 1 m2 of body surface area per day is recommended.

Children over 7 years of age are recommended 5000000 IU per 1 m2 of body surface area per day.

The drug is used 2 times a day every 12 hours for the first 10 days daily, then three times a week every other day for 6-12 months. Duration of treatment is determined by clinical efficacy and laboratory values.

The daily dose of the drug for each patient is calculated by multiplying the recommended dose for the given age by the body surface area calculated according to the nomogram for calculating the body surface area by height and weight according to Garford, Terry and Rourke. The single dose is calculated by dividing the calculated daily dose by 2 injections, the resulting value is rounded to the suppository dosage upwards.

In chronic viral hepatitis with severe activity and liver cirrhosis it is recommended to use VIFERON® 150000 IU in children under 7 years old, 500000 IU in 1 suppository 2 times a day after 12 hours daily for 14 days before plasmapheresis and/or hemosorption.

Infectious inflammatory diseases of urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults, including pregnant women in complex therapy.

The recommended dose for adults is VIFERON® 500000 IU in 1 suppository 2 times daily 12 hours for 5-10 days. The therapy can be continued if clinically indicated.

Pregnant women from the 2nd trimester of pregnancy (starting from the 14th week of gestation) should use the preparation VIFERON® 500000 IU in 1 suppository 12 hours a day for 10 days, and then for 9 days 3 times with an interval of 3 days (on the 4th day) in 1 suppository 2 times a day for 12 hours. Then every 4 weeks until delivery VIFERON® 150,000 IU

1 suppository 2 times a day every 12 hours daily for 5 days.

If necessary it is indicated to use VIFERON® 500000 IU 1 suppository 2 times daily after 12 hours for 10 days before childbirth (from the 38th week of gestation).

Primary or recurrent herpetic skin and mucous membrane infection, localized form, mild to moderate course, including urogenital form in adults including pregnant women.

The recommended dose for adults is VIFERON® 1000000 IU 1 suppository 2 times daily 12 hours a day for 10 days or more in cases of recurrent infection. Therapy may be continued if clinically indicated. It is recommended to start treatment as soon as the first signs of skin and mucous membrane lesions (itching, burning, reddening) appear.

In the treatment of recurrent herpes it is desirable to begin treatment in the prodromal period or at the very beginning of the manifestation of signs of relapse.

Pregnant women from the second trimester of pregnancy (starting from the 14th week of gestation) should use VIFERON® 500000 IU in 1 suppository every 12 hours daily for 10 days, then for 9 days 3 times with an interval of 3 days (on the fourth day) in 1 suppository 2 times daily in 12 hours. Then every 4 weeks until delivery VIFERON® 150,000 IU 1 suppository 2 times a day every 12 hours daily for 5 days. If necessary VIFERON® 500000 IU is indicated before childbirth (from 38 weeks of gestation) as 1 suppository 2 times daily 12 hours every 12 hours for 10 days.

Special Instructions

For the treatment of a wide range of infectious and inflammatory diseases Viferon may be used in combination therapy with antibacterial agents, glucocorticoids, immunosuppressive drugs.

There is evidence of the effectiveness of Viferon in the complex therapy and for the prevention of the following diseases and conditions: Herpetic infections, chlamydia, ureaplasmosis, toxoplasmosis, cytomegalovirus infection in adults and children over 1 year old; viral hepatitis in adults, acute respiratory infections, flu, bronchial asthma, juvenile rheumatoid arthritis; meningeal form of tick-borne encephalitis; prostatitis of various etiology; septic postoperative complications, virus-associated glomerulonephritis, pyelonephritis.

Contraindications

High sensitivity to the ingredients of the drug.

Side effects

In rare cases, allergic reactions (skin rashes, itching) may occur.

These phenomena are reversible and disappear 72 hours after discontinuation of the drug.

Pregnancy use

The drug is approved for use from 14 weeks of pregnancy. It has no restrictions to use during breastfeeding.

Similarities